Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OTX-TP · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| OTX-TP treatment | ACTIVE_COMPARATOR | OTX-TP (sustained release travoprost, 0.36 mg) to be used in this trial with placebo drops administered separately |
| Timolol control | ACTIVE_COMPARATOR | Timolol Maleate Ophthalmic Solution, 0.5% dosed twice daily (BID) in the presence of a placebo vehicle punctum plug (PV). |
| Name | Type | Description |
|---|---|---|
| OTX-TP | DRUG | OTX-TP and placebo drops |
| Timolol | DRUG | Timolol drops and placebo punctum plug |
Inclusion Criteria: * Subject must have a documented diagnosis of ocular hypertension, open angle glaucoma (with or without pseudoexfoliation or pigment dispersion component). * Subject has a mean baseline IOP following washout in at least 1 eye (the same eye) of ≥ 24mmHg at Hour 0 (T0) at Basel...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Timolol eye 0.5% |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Undisclosed |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| Alcon AG | ALC | 5 | N/A | Undisclosed |
| Sight Sciences, Inc. | SGHT | 3 | N/A | Undisclosed |
OTX-TP is an investigational small molecule being developed for the treatment of glaucoma. It is designed to be administered as an intracanalicular insert for sustained drug delivery. In clinical trials, it has been evaluated in patients with open angle glaucoma or ocular hypertension.
OTX-TP is a small molecule formulation of travoprost, a prostaglandin analog that lowers intraocular pressure by increasing aqueous humor outflow. It is being developed as a sustained-release intracanalicular insert for the treatment of glaucoma and ocular hypertension.
OTX-TP is being developed by Ocular Therapeutix, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol OCUL. The company is focused on ophthalmic therapies.
OTX-TP is in Phase 2 clinical development. A Phase 2b study has been completed, evaluating its safety and efficacy compared to timolol eye drops in patients with open angle glaucoma or ocular hypertension.
OTX-TP has been studied in one completed Phase 2b clinical trial, NCT02312544. This randomized, double-blind, active-controlled study enrolled 72 participants in the United States and compared OTX-TP to timolol drops in patients with open angle glaucoma or ocular hypertension.
OTX-TP is a proprietary formulation of travoprost, a prostaglandin analog used to lower intraocular pressure. While travoprost is the active pharmaceutical ingredient, OTX-TP is a sustained-release intracanalicular insert designed to deliver the drug over an extended period.